论文部分内容阅读
目的 :探讨阿奇霉素治疗支气管哮喘疗效及安全性。方法:50例支气管哮喘患者均为我院2016年2月—2017年2月期间收治,将其按照治疗方法的不同分为观察组25例和对照组25例,对照组患者采取常规治疗,观察组应用阿奇霉素治疗,对比两组患者的治疗效果及不良反应发生率。结果:观察组不良反应发生率为8.00%,治疗总有效率为96.00%;对照组不良发生率为40.00%,治疗总有效率为56.00%。两组比较差异有统计学意义(P<0.05)。结论:阿奇霉素治疗支气管哮喘疗效显著,不良反应少,安全性高,值得在临床上推广使用。
Objective: To investigate the efficacy and safety of azithromycin in the treatment of bronchial asthma. Methods: Fifty patients with bronchial asthma were admitted to our hospital from February 2016 to February 2017. According to the different treatment methods, they were divided into observation group (25 cases) and control group (25 cases). Patients in control group were treated routinely and observed Group treated with azithromycin, compared the two groups of patients and the incidence of adverse reactions. Results: The incidence of adverse reactions in the observation group was 8.00%, the total effective rate was 96.00%. In the control group, the incidence of adverse reactions was 40.00% and the total effective rate was 56.00%. The difference between the two groups was statistically significant (P <0.05). Conclusion: Azithromycin is effective in treating bronchial asthma with less side effects and high safety. It is worth to be popularized in clinic.